NEW RELEASES

NEW RELEASES :- Pharmatimes

Santersus advances nucleoCapture into pivotal sepsis study November 5, 2026
Axcellant appointed global CRO for multinational trial
John Pinching
Octane and Currus automate CUR‑001 manufacturing on cocoon platform November 5, 2026
Automation to support phase 1 solid tumour trial
John Pinching
Panthera expands Glasgow clinical research capacity November 4, 2026
New centre at health innovation hub boosts trial delivery
John Pinching
Exogenus leads €13 million EU project for secretome therapy November 4, 2026
Consortium to advance EXO‑101 for osteoarthritis
John Pinching
Vertex wins MHRA backing for wider Casgevy use November 3, 2026
UK authorisation and reimbursement extended to younger children
John Pinching
Qureight calls for fibrosis burden to lead imaging biomarkers November 3, 2026
Viewpoint urges shift in antifibrotic trial endpoints
John Pinching
Octane and Currus automate CAR T manufacturing on Cocoon November 2, 2026
Automation to support phase 1 solid tumour trial
John Pinching
Regulatory filings for lung cancer therapy advance November 2, 2026
Progress builds momentum for targeted Hutchmed and AstraZeneca treatment
John Pinching
Hansa reports positive PAES results for Idefirix at ASN Kidney Week October 29, 2026
One‑year graft failure‑free survival reaches 90% in crossmatch‑positive transplants
John Pinching
Hutchmed reports phase 3 SANOVO data for first‑line lung cancer October 29, 2026
Combination shows strong PFS and OS gains in MET‑overexpressing EGFRm disease
John Pinching

NEW RELEASES :- Pharma Voice

The end of MAHA?; Inovio’s big FDA win November 6, 2026
American voters turned their noses up at MAHA-aligned candidates this week; Inovio won a breakthrough nod for a DNA-based therapy.
PharmaVoice Staff
Ramaswamy’s biotech baggage haunted his political run November 5, 2026
A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.
Sy Mukherjee
The Democrats are coming. Here’s how they want to change pharma and healthcare. November 5, 2026
This week’s slate of Democratic winners have set their sights on expanding healthcare, removing RFK Jr. from HHS and pulling back the curtain on Trump’s secretive pharma deals.
Meagan Parrish
A push for speedier drug approvals doesn’t promise smooth market sailing November 4, 2026
Investors and payers sometimes balk at drugs approved on an accelerated pathway. Here’s how pharma can de-risk these medications while they’re still in development.
Alexandra Pecci
Lilly’s R&D whirlwind — what the large pharma has taken in and what it’s dropped November 3, 2026
While its GLP-1 franchise is still booming, prospects in other arenas haven’t panned out. Here’s a look at where Lilly’s investing the candidates it’s recently had to drop.
Kelly Bilodeau
How well is J&J’s incubator model working? November 2, 2026
After incubating about 1,200 companies, the pharma giant is putting less emphasis on physical lab space — and taking a more targeted approach to new science.
Meagan Parrish
How can biopharma overcome digital transformation failure? November 2, 2026
Explore the barriers keeping biopharma from turning digital investment into real impact.
Martin Ball, Senior product marketing manager, automation and digital
Making oral drug delivery more sustainable with measurable product-level data November 2, 2026
How auditable LCA data can guide more informed sustainability decisions.
Keytruda biosims are coming — but they face an uphill battle October 30, 2026
The dreaded patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
Kelly Bilodeau
Anthropic’s historic IPO; Akeso’s big clinical showing October 30, 2026
Anthropic is setting the stage for the largest IPO in history and Akeso has been touting its latest positive results for its buzzy bispecific.
PharmaVoice Staff

[wp-rss-aggregator feeds="pharmexec-com"]

[wp-rss-aggregator feeds="pharmiweb-com-articles"]

Santersus advances nucleoCapture into pivotal sepsis study
Axcellant appointed global CRO for multinational trial
Octane and Currus automate CUR‑001 manufacturing on cocoon platform
Automation to support phase 1 solid tumour trial
Panthera expands Glasgow clinical research capacity
New centre at health innovation hub boosts trial delivery
Exogenus leads €13 million EU project for secretome therapy
Consortium to advance EXO‑101 for osteoarthritis
Vertex wins MHRA backing for wider Casgevy use
UK authorisation and reimbursement extended to younger children
Qureight calls for fibrosis burden to lead imaging biomarkers
Viewpoint urges shift in antifibrotic trial endpoints
Octane and Currus automate CAR T manufacturing on Cocoon
Automation to support phase 1 solid tumour trial
Regulatory filings for lung cancer therapy advance
Progress builds momentum for targeted Hutchmed and AstraZeneca treatment
Hansa reports positive PAES results for Idefirix at ASN Kidney Week
One‑year graft failure‑free survival reaches 90% in crossmatch‑positive transplants
Hutchmed reports phase 3 SANOVO data for first‑line lung cancer
Combination shows strong PFS and OS gains in MET‑overexpressing EGFRm disease

GMP and Quality

Non-conformances in Pharmaceutical Laboratories

Pharma VedMay 8, 2024

Pharmaceutical quality control laboratories are the guardians of public health. Through meticulous testing of raw materials, in-process materials, and finished products, they ensure the safety and efficacy of medications. However, nonconformances can arise...